A Phase 4 interventional study of Atorvastatin 80mg and Atorvastatin 20mg in Mechanical Thrombectomy and Acute Ischemic Stroke, sponsored by Zhongda Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-23.
Sponsored by Zhongda Hospital · Phase 4, Interventional, and Treatment
This project investigates the impact of statins on cerebral vascular wall damage after mechanical thrombectomy. The investigators will undertake a multi-center, prospective, parallel-controlled, open-label, superiority randomized controlled study based on past research on intense lipid-lowering intervention trials. Patients undergoing post-thrombectomy will be divided into two groups: the test group and the control group. After surgery, the test group will be given a high dose of atorvastatin (80mg/day), followed by a standard dose (20mg/day). The control group will continue to receive the standard dose of atorvastatin (20mg/day). The investigators will compare the high-resolution vascular wall MRI characteristics (vascular wall enhancement, lumen stenosis rate, and so on) within 3-5 days of the operation, as well as the composite incidence of ischemic stroke, transient ischemic attack, intracranial hemorrhage 1 month postoperatively, and the modified Rankin Score at 90 days.
2,593 studies on the registry are indexed under Ischemic Stroke; 930 are open to participants now.
This study's planned enrollment of 162 is above the median of 120 across 1,752 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Zhongda Hospital is the lead sponsor of 101 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the mechanical embolectomy, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
Drug: Atorvastatin 80mg
a standard dose (20mg/day) of atorvastatin after the mechanical embolectomy
Drug: Atorvastatin 20mg
The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
Cerebral vascular wall damage
Incidence of T1 hyperintensity and T1 shortening within the arterial wall in HR-VWI
Time frame: within 5-7 days after MT
Target vessel stenosis rate
The stenosis rate of target blood vessel artery 5-7 days after MT surgery.
Time frame: Within 5-7 days after MT
Perioperative complications
Cumulative incidence rate of symptomatic intracranial hemorrhage, TIA or ischemic stroke within 30 days after MT surgery.
Time frame: Within 30 days after MT
Neurological function evaluation
Proportion of patients with good prognosis 3 months after MT surgery.
Time frame: Within 90 days after MT
Plan to share: No
This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongda Hospital